GRI Bio (NASDAQ: GRI) Participates in Virtual Investor What This Means Segment Highlighting Positive Preclinical Data from Idiopathic Pulmonary Fibrosis (IPF) and Systemic Lupus Erythematosus (SLE) Programs tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
The company unveiled a series of new studies highlighting the prognostic value of its imaging biomarkers in patients with fibrotic lung diseaseThe studies reflect the company's expanding Life
SOUTH SAN FRANCISCO, Calif., May 21, 2024 Pliant Therapeutics, Inc. , a clinical-stage biotechnology company and leader in the discovery and development of novel therapeutics for the treatment.
STOCKHOLM, SWEDEN / ACCESSWIRE / May 20, 2024 / Vicore Pharma Holding (STO:VICO)Buloxibutid improved lung function-measured by FVC-by over 200 mL from baseline at 36 weeks of treatment.The therapy was safe and well tolerated with no treatment-related serious adverse events.Biomarker analysis reflected an increase in.
GRI Bio Presents Positive Preclinical Data Demonstrating Lead Program GRI-0621 Reduces the Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF) tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.